Skip to main content
Home > BioCentury on BioBusiness > Finance/Investment

Chronological Index of : Finance

 Current Issue
  • Volatile, not futile

    Biotech turned red in 3Q15 but bankers, buysiders say it's the lone growth sector

    Pricing is on the radar of generalist investors, and likely will remain an issue through next year's presidential election in the U.S.

    Published on 10/5/2015
  • Drawn and quartered

    Biotech winners, losers in 3Q15

    3Q15 saw every biotech market cap band post big losses, although a few winners emerged in each group.

    Published on 10/5/2015
  • Figure: London vs. Europe

    Drawn and quartered London vs. Europe Despite massive declines in the U.S.-centric biotech indices, the BioCentury Europe declined just 1% in 3Q15, and the BioCentury London dropped just 0.2%. The market cap-…

    Published on 10/5/2015
  • Figure: Price-to-earnings: BT vs. RX

    Drawn and quartered Price-to-earnings: BT vs. RX The average P/E for big biotechs ended the quarter at 20.2, the lowest level since 4Q12, when the multiple was 18.4. The group's P/E is down 23% from 2Q15 and 8% …

    Published on 10/5/2015
  • Figure: Results by market cap

    Drawn and quartered Results by market cap All market cap segments ended the quarter down by more than 15%, led by a 22.2% decline in the group of companies valued at $500-$999 million. The decline across the board…

    Published on 10/5/2015
  • Table: 3Q approvals

    Drawn and quartered 3Q approvals Selected third quarter approvals. Company Approval AbbVie Inc. (NYSE:ABBV) FDA approves Technivie ombitasvir/paritaprevir/ritonavir in combination with ribavirin to treat non-…

    Published on 10/5/2015
  • Table: Index performance

    Drawn and quartered Index performance Index 3Q15 YTD BioCentury London 0% 6% BioCentury Europe -1% 18% S&P 500 -7% -7% NASDAQ Composite -7% -2% DJIA -8% -9% NYSE Arca Pharmaceutical -9% -2% …

    Published on 10/5/2015
  • Table: Restructuring watch

    Drawn and quartered Restructuring watch At least one company reported workforce reductions in the third quarter compared to at least eight in the same period last year. This is the smallest number since 4Q14 and …

    Published on 10/5/2015
  • Table: 4Q15 milestones

    Event planner 4Q15 milestones Selected products with Phase III or regulatory milestones expected in 4Q15. Source: BCIQ: BioCentury Online Intelligence Company Product Indication Event Milestone AbbVie Inc.…

    Published on 10/5/2015
  • Lighting up neoantigens

    How Third Rock start-up Neon plans to tap neoantigen biology for cancer

    Finance Ebb & Flow Lighting up neoantigens Figure: Money Raised in 2015 Investors led by Third Rock Ventures put $55 million into Neon Therapeutics Inc. to exploit recently discovered neoantigen biology from …

    Published on 10/5/2015
  • Event planner

    Investors' top names, milestones and meetings in 4Q15

    Buysiders interested in putting money to work in 4Q15 have a full plate of late-stage milestones to look forward to.

    Published on 10/5/2015
  • Figure: Money Raised in 2015

    Lighting up neoantigens Money Raised in 2015 Last week, the biotech industry raised $732 million, bringing to $96.2 billion the total raised year-to-date. In 2014, a total of $54.9 billion was raised, including $…

    Published on 10/5/2015
  • Figure: Biotech fund flows

    Volatile, not futile Biotech fund flows Despite outflows in the past two months, biotech funds saw net inflows of $503.3 million during 3Q and $6.3 billion for the first three quarters of 2015. The September fund …

    Published on 10/5/2015
  • Figure: Cranking the volume

    Volatile, not futile Cranking the volume Since Hillary Clinton's "price gouging" tweet on Sept. 21, the iShares NASDAQ Biotechnology ETF (IBB) is down 12%, with average daily trading volume of 5.9 million shares.…

    Published on 10/5/2015
  • Table: Follow-on performance

    Volatile, not futile Follow-on performance Forty-six biotechs raised $5.4 billion, bringing the year-to-date tally to $24.5 billion, more than any amount raised in a full year since BioCentury started tracking …

    Published on 10/5/2015
  • Table: IPO performance

    Volatile, not futile IPO performance In 3Q15, 15 biotechs raised $1.8 billion in IPOs, down from 30 for $3 billion in 3Q14. The last time 15 IPOs or fewer were completed in a quarter was in 1Q13, when seven …

    Published on 10/5/2015
  • Table: IPO queue

    Volatile, not futile IPO queue Nineteen companies have announced plans to go public since the start of 3Q15, bringing the IPO queue to at least 28. Unless noted, companies are seeking to list on NASDAQ. Most …

    Published on 10/5/2015
  • Back to the bone

    Why OrbiMed's Stephen Squinto is buying back into bone biology

    Finance Back to the bone In one of his first investments since joining OrbiMed Advisors in January, Stephen Squinto is returning to a space he knows well — biologics for an Orphan bone disease. The result was …

    Published on 10/5/2015
  • Asceneuron's clinical path

    Why Sofinnova Partners led preclinical tau biology play Asceneuron's A round

    Finance Asceneuron's clinical path Investors pulled the trigger on a CHF30 million ($30.7 million) A round for preclinical neurology play Asceneuron S.A. last week thanks to a combination of in vivo proof-of-…

    Published on 10/5/2015
  • Forbion goes to Spain

    How Forbion found its first Spanish investment in Laboratoris Sanifit

    Finance Forbion goes to Spain Dutch VC Forbion Capital Partners has spent years scouring the Iberian peninsula for investments, but always encountered two problems: unrealistic valuations or inexperienced …

    Published on 9/28/2015
  • Loose lips

    Looking at value lost over three decades of the Clintons talking biotech

    Ebb & Flow Ebb & Flow Loose lips Figure: Money Raised in 2015 When it comes to Clinton proclamations that destroy value in the biotech sector, Hillary holds the market cap title but Bill still has the record in…

    Published on 9/28/2015
  • Figure: Money Raised in 2015

    Loose lips Money Raised in 2015 Last week, the biotech industry raised $1,116 million, bringing to $95.4 billion the total raised year-to-date. In 2014, a total of $54.9 billion was raised, including $21.5 billion…

    Published on 9/28/2015
  • Play it again

    Why Atlas is backing oncolytic virus company Replimune

    Finance Play it again Atlas Venture's decision to seek out an oncolytic virus investment coincided with the ex-management of BioVex Inc. looking to reunite to develop a next-generation product. The result was last …

    Published on 9/28/2015
  • Deep pockets

    Why Deciphera thinks the time was right to tap VC money

    Finance Deep pockets With four unpartnered cancer compounds in or entering the clinic, Deciphera Pharmaceuticals LLC decided it was finally time to raise venture money. Last week's $75 million series B round from a…

    Published on 9/28/2015
  • Figure: Money Raised in 2015

    Flower power Money Raised in 2015 Last week, the biotech industry raised $6,657 million, bringing to $94 billion the total raised year-to-date. In 2014, a total of $54.9 billion was raised, including $21.5 billion…

    Published on 9/21/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993